1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
5.19(c) 5.35(c) 5.14(c) 5.2(c) 4.89 Last
34 336 48 823 39 642 17 872 72 745 Volume
-2.08% +3.08% -3.93% +1.17% -5.96% Change
More quotes
Estimated financial data (e)
Sales 2022 1,25 M 1,34 M 1,34 M
Net income 2022 -52,1 M -55,9 M -55,9 M
Net Debt 2022 24,4 M 26,2 M 26,2 M
P/E ratio 2022 -3,47x
Yield 2022 -
Sales 2023 1,36 M 1,46 M 1,46 M
Net income 2023 -102 M -109 M -109 M
Net Debt 2023 2,66 M 2,86 M 2,86 M
P/E ratio 2023 -3,35x
Yield 2023 -
Capitalization 170 M 183 M 183 M
EV / Sales 2022 156x
EV / Sales 2023 127x
Nbr of Employees 100
Free-Float 94,5%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the... 
Sector
Biotechnology & Medical Research
Calendar
05/24 | 11:30amPresentation
More about the company
Ratings of Nanobiotix
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NANOBIOTIX
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/18NANOBIOTIX : 1st quarter results
CO
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/30NANOBIOTIX : Monthly statement on outstanding equity shares and voting rights
CO
04/11Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun..
MT
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
04/11NANOBOTIX :  New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation ..
BU
04/11Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the ..
CI
04/11NANOBIOTIX : Press Release, dated April 08, 2022 - Form 6-K
PU
04/11NANOBIOTIX : Report
CO
04/11NANOBIOTIX : SEC Filing 20 F
CO
More news
News in other languages on NANOBIOTIX
05/19NANOBIOTIX : visibilité financière jusqu’au quatrième trimestre 2023
05/19Un pas en avant, deux pas en arrière
05/19EN DIRECT DES MARCHES : Veolia, Société Générale, L'Oréal, Stellantis, EDF, Derichebourg, ..
05/18CORRIGE ET REMPLACE : Nanobiotix fait le point sur ses activités et publie ses résultats f..
05/18Nanobiotix fait le point sur ses activités et publie ses résultats financiers pour le p..
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,20 €
Average target price 22,90 €
Spread / Average Target 340%
EPS Revisions
Managers and Directors
Laurent Lévy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX-28.86%194
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688